99 related articles for article (PubMed ID: 17536105)
21. Radiosensitizers in the treatment of squamous cell carcinoma of the head and neck.
Dische S
Clin Otolaryngol Allied Sci; 1977 Nov; 2(4):403-9. PubMed ID: 340084
[No Abstract] [Full Text] [Related]
22. Uroporphyrinogen decarboxylase: optimizing radiotherapy for head and neck cancer.
Ito E; Yip KW; Liu FF
Future Oncol; 2011 May; 7(5):595-7. PubMed ID: 21568673
[No Abstract] [Full Text] [Related]
23. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients.
Thorwarth D; Eschmann SM; Holzner F; Paulsen F; Alber M
Radiother Oncol; 2006 Aug; 80(2):151-6. PubMed ID: 16920211
[TBL] [Abstract][Full Text] [Related]
24. The use of radioimmunotherapy in combination with bioreductive agents.
Langmuir VK
Recent Results Cancer Res; 1996; 141():137-43. PubMed ID: 8722424
[No Abstract] [Full Text] [Related]
25. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome: in regard to Evans et al. (Int J Radiat Oncol Biol Phys 2007;69:1024-1031).
Bussink J; van der Kogel AJ; Kaanders JH
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1616. PubMed ID: 18374238
[No Abstract] [Full Text] [Related]
26. Insights into the relationship between HPV/p16 status, hypoxia imaging and treatment outcomes in head and neck cancer.
Porceddu SV
J Med Imaging Radiat Oncol; 2014 Feb; 58(1):98-100. PubMed ID: 24529062
[No Abstract] [Full Text] [Related]
27. Radiosensitization by misonidazole (Ro 07-0582). The importance of timing and tumor concentration of sensitizer.
McNally NJ; Denekamp J; Sheldon P; Flockhart IR; Stewart FA
Radiat Res; 1978 Mar; 73(3):568-80. PubMed ID: 273269
[No Abstract] [Full Text] [Related]
28. DNA damage induced in T50/80 tumour cells following exposure to the bioreductive drug Tirapazamine in combination with a single dose of radiation (12Gy).
Friery OP; Hejmadi MV; McKeown SR
Biochem Soc Trans; 1997 Feb; 25(1):135S. PubMed ID: 9057033
[No Abstract] [Full Text] [Related]
29. The response of a transplantable tumor to fractionated irradiation. II. Fast neutrons.
Denekamp J; Harris SR; Morris C; Field SB
Radiat Res; 1976 Oct; 68(1):93-103. PubMed ID: 967976
[No Abstract] [Full Text] [Related]
30. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia.
Yang DJ; Wallace S; Cherif A; Li C; Gretzer MB; Kim EE; Podoloff DA
Radiology; 1995 Mar; 194(3):795-800. PubMed ID: 7862981
[TBL] [Abstract][Full Text] [Related]
31. Novel radiation sensitizers targeting tissue hypoxia.
Rowinsky EK
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):61-70. PubMed ID: 10550828
[TBL] [Abstract][Full Text] [Related]
32. Improving the effectiveness of the bioreductive antitumor agent SR 4233 by induced hypoxia.
Minchinton AI; Brown JM
Adv Exp Med Biol; 1992; 317():177-81. PubMed ID: 1288125
[No Abstract] [Full Text] [Related]
33. Combined treatment techniques in head and neck cancer: radiation therapy, chemotherapy and hyperthermia.
Brady LW
Laryngoscope; 1978 Jan; 88(1 Pt 2 Suppl 8):68-74. PubMed ID: 619215
[No Abstract] [Full Text] [Related]
34. [Docetaxel in the inductive therapy of head and neck cancer: recent evidence].
Benasso M; Corvò R
Tumori; 2008; 94(4):suppl 24-5. PubMed ID: 18822713
[No Abstract] [Full Text] [Related]
35. Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.
Troost EG; Laverman P; Kaanders JH; Philippens M; Lok J; Oyen WJ; van der Kogel AJ; Boerman OC; Bussink J
Radiother Oncol; 2006 Aug; 80(2):157-64. PubMed ID: 16905213
[TBL] [Abstract][Full Text] [Related]
36. [Studies on the radiation sensitizing effect of 6-anaurazilribosid depending on the irradiation time in the Ehrlich tumor].
Magdon E; Konopatzky R; Sterescu M
Strahlentherapie; 1968 Aug; 136(2):237-40. PubMed ID: 5695894
[No Abstract] [Full Text] [Related]
37. Enhancement of radiation response of a murine mammary carcinoma by two nitrofuran derivatives.
Stone HB; Withers HR
Radiat Res; 1975 Dec; 64(3):443-51. PubMed ID: 128031
[No Abstract] [Full Text] [Related]
38. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio.
Lehtiö K; Oikonen V; Nyman S; Grönroos T; Roivainen A; Eskola O; Minn H
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):101-8. PubMed ID: 12483416
[TBL] [Abstract][Full Text] [Related]
39. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer.
Thorwarth D; Eschmann SM; Scheiderbauer J; Paulsen F; Alber M
BMC Cancer; 2005 Dec; 5():152. PubMed ID: 16321146
[TBL] [Abstract][Full Text] [Related]
40. Combination of chemotherapy with radiotherapy: review of previous studies and new perspectives.
Clavel M; Ardiet JM; Gignoux B
Int J Clin Pharmacol Res; 1985; 5(4):279-82. PubMed ID: 2414237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
